We observed significantly increased sensitivity to the PLK1 inhibitors GW843682X and BI-2536 in cancer cell lines with FA pathway mutations compared with those with WT FA genes (Supplementary Fig. S1C and S1D; Supplementary Datasets S2–S5). The gene discussed is PLK1; the disease is Friedreich ataxia.